Advertisement
UK markets close in 4 hours 36 minutes

  • FTSE 100

    8,209.52
    +37.37 (+0.46%)
     

  • FTSE 250

    20,072.13
    +19.80 (+0.10%)
     

  • AIM

    770.35
    +2.24 (+0.29%)
     

  • GBP/EUR

    1.1684
    +0.0001 (+0.01%)
     

  • GBP/USD

    1.2555
    +0.0022 (+0.18%)
     

  • Bitcoin GBP

    46,915.03
    +894.72 (+1.94%)
     

  • CMC Crypto 200

    1,281.59
    +4.61 (+0.36%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CRUDE OIL

    79.17
    +0.22 (+0.28%)
     

  • GOLD FUTURES

    2,309.10
    -0.50 (-0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    17,983.92
    +87.42 (+0.49%)
     

  • CAC 40

    7,958.94
    +44.29 (+0.56%)
     
PROPERTY:

11 fabulous farmhouses perfect for living a rural lifestyle

A farmhouse could be your dream home if you’re in search of bucolic bliss

Lonza names Siegfried Holding boss as new CEO

Reuters
·1-min read
Logo of Swiss contract drug maker Lonza is seen in Basel

ZURICH (Reuters) -Swiss contract drug manufacturer Lonza on Tuesday named Wolfgang Wienand, CEO of Siegfried Holding, as its new chief executive.

Wienand, who has led the Swiss contract development and manufacturing (CDMO) company since 2019, will replace Chairman Albert Baehny, who has served as interim CEO at Lonza since October 2023.

Wienand will join Basel-based Lonza in the summer of 2024, the company said, while Baehny will retire following a transition period.

Before becoming CEO at Siegfried, Wienand was chief scientific officer and chief strategy officer at the company, which produces pharmaceutical ingredients and finished products.

ADVERTISEMENT

"The board is delighted to have appointed a seasoned CEO with a strong and established track record of success in the CDMO industry," Baehny said in a statement.

"Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise," he added.

(Reporting by John Revill, Editing by Rachel More)